|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Stakeholder Opinions: Kidney Transplantation - Switching to calcineurin inhibitor-free immunosuppression |
|
|
|
|
€ 3 040,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Avril 2006 |
Taille du document : |
88 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The Pharmaceutical Distribution Outlook 1998-2008
165 pages | Octobre 1998 |
Industry growth and consolidation means that pharmaceutical manufacturers are no longer geographically limited in their operations and now market their products globally, creating a vast commercia |
795,00 €
|
| |
| |
The Japanese Pharmaceutical Market Outlook 2001
142 pages | Août 2001 |
Although Japan is the second largest pharmaceutical market in the world, it has traditionally been a relative 'no-go' area for pre-eminent Western drug companies.
Now, however, extensive cultur |
1 200,00 €
|
| |
| |
The Pharmaceutical Mergers and Acquisitions Outlook 2001
128 pages | Octobre 2001 |
Pharmaceutical companies have recently undertaken extensive M&A activity to either build critical mass, create organic growth or through strategic alliances to build virtual mass.
The Pharmaceu |
1 200,00 €
|
| |
| |
The Pharmaceutical industry in the 21st Century
150 pages | Octobre 1998 |
Does the 21st century herald the beginning of a genomics revolution? Which disease areas will provide the greatest growth potential and why? Which technologies have the greatest potential to max |
795,00 €
|
| |
| |
ePharmacies: Strategic Implications for the Healthcare Industry
230 pages | Mars 2000 |
Increasingly, the pharmaceutical sector is being influenced by the Internet.Are you in a position to:- Predict future shifts in drug prescribing and purchasing behavior?- Anticipate consolidation in b |
955,00 €
|
| |
| |
The Drug Discovery Outlook: Drivers of innovation in the 21st Century
189 pages | Octobre 2000 |
The Drug Discovery Outlook: Drivers of innovation in the 21st Century introduces and analyzes the five key enabling technologies and bioinformatics, which are currently driving pharmaceutical dru |
955,00 €
|
| |
| |
The Global Parallel Trade Outlook 2001 - 2006: A Country-by-Country Analysis
188 pages | Septembre 2001 |
Global Parallel Trade Outlook 2001: A country-by-country analysis, a new report by Reuters Business Insight, provides a detailed update on the status of parallel trade in the global marketplace.
1 200,00 €
|
|
| |
| |
The Drug Delivery Outlook to 2005
150 pages | Février 1999 |
Strategic overview : defines and values the market covered in the report, provides a macro analysis of the reasons why the drug delivery sector is growing at current rates and predicts how the c |
795,00 €
|
| |
| |
The Evolution of DTC marketing across key pharmaceutical markets
152 pages | Mars 2000 |
Pharmaceutical companies mainly market their products through contact between their sales force and heathcare providers.
However, due to the nature of its products, the pharmaceutical industry |
955,00 €
|
| |
| |
Pfizer's Recent Takeover
15 pages | Juillet 2002 |
On 15th July 2002, Pfizer announced the acquisition of Pharmacia in a stock-for-stock transaction valued at $60 billion, expanding the company's core strengths in pharmaceuticals and health care.
|
300,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Stakeholder Opinions: Kidney Transplantation - Switching to calcineurin inhibitor-free immunosuppression |
|
|
Introduction
In 2005, around 30,000 renal transplants were conducted in the seven major markets. In order to prevent the patient’s immune system from rejecting the transplanted organ, daily immunosuppression therapy is a necessity for the lifetime of the graft with a base maintenance drug (cyclosporine, tacrolimus, sirolimus) combined with adjunctive therapies (azathioprine, mycophenolate mofetil, steroids).
Scope
Historical and recent trends in immunosuppressive therapy including current clinical practice and clinical advantages and side effects of treatments
Organ supply, national donation rates, waiting lists and forecasts of the number of transplants and maintenance populations to 2015
Primary diagnosis, graft survival rates, reasons for late graft failure and risk factors associated with acute rejection
Future market outlook including calcineurin inhibitor avoidance/withdrawal strategies
Report Highlights
30,000 renal transplants were performed in 2005, increasing to 43,000 by 2015 (CAGR, 2005-15, 4%), although the “organ gap” may widen further as increasing morbidity, such as diabetes mellitus, drives demand.
The number of patients with functioning kidney transplants will double to 428,000 by 2015, creating a large group of patients with unique and complex long-term medical care needs directly attributable to adverse effects of immunosuppressive drugs, including nephrotoxicity, diabetes, hypertension, hyperlipidemia and vulnerability to infection.
Although prevention of acute rejection remains a primary treatment goal, agents that do not impair long-term renal function are required. While results from sirolimus based calcineurin-inhibitor withdrawal regimens are inconclusive more promising results are emerging from use in the calcineurin-inhibitor avoidance or switching setting.
Reasons to Purchase
Identify changing trends in immunosuppressive protocols
Understand the most common treatment protocols in renal transplantation by patient type
Quantify the future market size based on the number of transplants and renal maintenance populations
|
|
Introduction
In 2005, around 30,000 renal transplants were conducted in the seven major markets. In order to prevent the patient’s immune system from rejecting the transplanted organ, daily immunosuppression therapy is a necessity for the lifetime of the graft with a base maintenance drug (cyclosporine, tacrolimus, sirolimus) combined with adjunctive therapies (azathioprine, mycophenolate mofetil, steroids).
Scope
Historical and recent trends in immunosuppressive therapy including current clinical practice and clinical advantages and side effects of treatments
Organ supply, national donation rates, waiting lists and forecasts of the number of transplants and maintenance populations to 2015
Primary diagnosis, graft survival rates, reasons for late graft failure and risk factors associated with acute rejection
Future market outlook including calcineurin inhibitor avoidance/withdrawal strategies
Report Highlights
30,000 renal transplants were performed in 2005, increasing to 43,000 by 2015 (CAGR, 2005-15, 4%), although the “organ gap” may widen further as increasing morbidity, such as diabetes mellitus, drives demand.
The number of patients with functioning kidney transplants will double to 428,000 by 2015, creating a large group of patients with unique and complex long-term medical care needs directly attributable to adverse effects of immunosuppressive drugs, including nephrotoxicity, diabetes, hypertension, hyperlipidemia and vulnerability to infection.
Although prevention of acute rejection remains a primary treatment goal, agents that do not impair long-term renal function are required. While results from sirolimus based calcineurin-inhibitor withdrawal regimens are inconclusive more promising results are emerging from use in the calcineurin-inhibitor avoidance or switching setting.
Reasons to Purchase
Identify changing trends in immunosuppressive protocols
Understand the most common treatment protocols in renal transplantation by patient type
Quantify the future market size based on the number of transplants and renal maintenance populations
|
|
|
PPLSEN
|
|
|
|
|
